Lv22
110 积分 2022-06-22 加入
Discovery and Characterization of RP03707: A Highly Potent and Selective KRASG12D PROTAC
7小时前
已完结
Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
1天前
已完结
The phase II MutHER study of neratinib alone and in combination with fulvestrant in HER2 mutated, non-amplified metastatic breast cancer
3个月前
已完结
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
3个月前
已完结
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial
4个月前
已完结
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study
4个月前
已完结
CNS activity of trastuzumab deruxtecan in HER2-expressing non-small-cell lung cancer
4个月前
已完结
Cancer cell metabolism and antitumour immunity
4个月前
已完结
MYO1F positions cGAS on the plasma membrane to ensure full and functional signaling
4个月前
已完结
BAY 2927088: The first non-covalent, potent, and selective tyrosine kinase inhibitor targeting EGFR exon 20 insertions and C797S resistance mutations in NSCLC
5个月前
已完结
皖公网安备34019202002308
